obes
worldwid
epidem
lead
develop
chronic
metabol
disord
type
diabet
cardiovascular
diseas
nonalcohol
fatti
liver
diseas
nalfd
nafld
condit
fat
mainli
triglycerid
tg
accumul
hepatocyt
patient
consum
excess
amount
alcohol
estim
preval
nafld
rang
depend
popul
expect
rise
obes
rate
increas
popul
becom
older
physic
activ
level
decreas
moreov
increas
preval
nafld
patient
sever
may
aggrav
howev
beyond
epidemiolog
mani
challeng
diagnosi
treatment
nafld
patient
nafld
mostli
asymptomat
gold
standard
diagnosi
base
liver
biopsi
highli
invas
expens
altern
imag
techniqu
ultrasound
us
comput
tomographi
magnet
reson
imag
use
nafld
diagnosi
among
method
abdomin
us
commonli
use
due
rel
low
expens
howev
major
drawback
us
includ
inabl
quantifi
liver
fat
amount
variabl
due
examin
techniqu
recent
novel
physic
index
call
control
attenu
paramet
cap
develop
base
properti
ultrason
signal
examin
transient
liver
elastographi
echosen
pari
franc
cap
reli
concept
fat
attenu
us
propag
noninvas
quantiz
ultrason
attenu
center
frequenc
probe
mhz
furthermor
larg
prospect
studi
demonstr
accuraci
cap
diagnos
nafld
despit
increas
number
patient
diagnos
nafld
optim
therapeut
agent
manag
nafld
american
associ
studi
liver
diseas
aasld
american
gastroenterolog
associ
aga
recommend
vitamin
e
supplement
nafld
patient
without
diabet
thiazolidinedion
tzd
nafld
patient
diabet
tzd
potent
peroxisom
proliferatoractiv
receptor
gamma
agonist
lower
blood
glucos
level
amelior
system
insulin
sensit
inflamm
recent
novel
tzd
call
lobeglitazon
develop
current
prescrib
korea
efficaci
safeti
lobeglitazon
wellinvestig
identifi
better
treatment
option
patient
nafld
investig
effect
lobeglitazon
patient
analyz
alter
cap
valu
use
transient
liver
elastographi
well
glycem
lipid
liver
profil
particip
consid
elig
studi
diagnos
year
old
particip
also
drugfre
three
month
valu
mm
take
stabl
dose
metformin
valu
mm
time
screen
subject
exclud
consum
gweek
alcohol
male
gweek
femal
posit
hepat
b
c
type
diabet
secondari
diabet
subject
histori
renal
dysfunct
serum
creatinin
mgdl
male
mgdl
femal
heart
failur
new
york
heart
associ
nyha
class
iii
iv
uncontrol
heart
arrhythmia
cardiocerebr
event
unstabl
angina
myocardi
infarct
transient
ischem
attack
cerebr
infarct
hemorrhag
within
period
prior
screen
exclud
subject
histori
corticosteroid
treatment
least
day
within
twomonth
period
prior
screen
cancer
treatment
includ
chemo
radiotherapi
within
two
year
also
exclud
pregnant
women
nurs
mother
exclud
remain
subject
nafld
confirm
cap
valu
dbm
enrol
studi
prospect
singlearm
openlabel
clinic
trial
elleg
efficaci
safeti
use
lobeglitazon
patient
nonalcohol
fatti
liver
diseas
trial
conduct
five
tertiari
medic
center
korea
evalu
efficaci
safeti
use
oncedaili
lobeglitazon
mg
treat
patient
nafld
patient
valu
exceed
week
treatment
rescu
medic
mg
glimepirid
introduc
primari
endpoint
chang
cap
measur
transient
elastographi
baselin
end
lobeglitazon
treatment
secondari
endpoint
chang
baselin
multipl
valu
paramet
includ
fast
plasma
glucos
fpg
glycat
albumin
ga
liver
enzym
aspart
transaminas
ast
alanin
transaminas
alt
gamma
glutamyl
transferas
lipid
profil
compon
lowdens
lipoprotein
cholesterol
ldlc
highdens
lipoprotein
cholesterol
hdlc
total
cholesterol
tc
tg
highsensit
creactiv
protein
hscrp
addit
alter
baselin
homeostasi
model
assess
insulin
resist
homair
quantifi
base
fpg
fast
insulin
level
use
secondari
endpoint
studi
period
patient
visit
clinic
initi
screen
baselin
measur
addit
week
initi
screen
visit
fast
blood
sampl
subject
well
urin
pregnanc
test
femal
particip
childbear
age
taken
laboratori
assess
baselin
visit
cap
liver
us
perform
visit
cap
perform
enter
studi
assess
daili
dietari
exercis
routin
particip
educ
ask
maintain
calori
limiteddiet
perform
minweek
mediumintens
aerob
exercis
use
hexokinas
method
measur
fpg
level
enzymat
colorimetr
method
measur
tg
tc
ldlc
hdlc
level
serum
level
liver
enzym
profil
measur
standard
method
hospit
ionexchang
highperform
liquid
chromatographi
biorad
laboratori
hercul
ca
usa
use
measur
level
serum
ga
level
measur
enzymat
method
use
lucica
gal
reagent
asahi
kasei
pharma
co
tokyo
japan
hitachi
p
modul
autoanalyz
hitachi
instrument
servic
tokyo
japan
use
right
lobe
liver
intercost
space
obtain
cap
valu
liver
stiff
measur
lsm
describ
previous
cap
assess
use
fibroscan
echosen
place
tip
probe
skin
rib
right
lobe
liver
ensur
accur
cap
valu
calcul
us
attenu
match
lsm
valid
attempt
collect
valid
lsm
success
rate
ratio
interquartil
rang
iqr
median
valu
lsm
iqrmlsm
consid
reliabl
use
final
analysi
cap
valu
measur
train
oper
follow
manufactur
instruct
steatosi
grade
determin
use
follow
capcutoff
valu
previous
report
sasso
et
al
dbm
dbm
dbm
us
scan
perform
profession
radiologist
us
perform
investig
studi
endpoint
mere
use
rule
liver
disord
us
method
devic
standard
safeti
assess
everi
visit
via
patientreport
advers
event
physic
examin
regular
monitor
multipl
paramet
includ
vital
sign
laboratori
test
result
peripher
edema
defin
increas
ankl
circumfer
baselin
also
monitor
along
pit
edema
continu
variabl
express
mean
standard
deviat
sd
ast
alt
tg
valu
log
transform
valu
distribut
skew
student
ttest
pearson
test
use
continu
categor
variabl
respect
evalu
differ
accord
lobeglitazon
respons
respond
lobeglitazon
defin
individu
show
decreas
cap
treatment
chang
clinicolaboratori
paramet
includ
cap
valu
lobeglitazon
treatment
evalu
use
pair
ttest
perform
correl
analys
examin
relationship
chang
cap
valu
clinicolaboratori
paramet
baselin
treatment
multivari
linear
regress
analysi
perform
assess
associ
cap
valu
chang
variou
clinicolaboratori
paramet
result
express
valu
standard
std
p
valu
twosid
p
valu
consid
signific
statist
analys
conduct
use
spss
window
softwar
version
spss
inc
chicago
il
usa
studi
compli
declar
helsinki
regist
clinicaltrialsgov
registr
identif
number
clinic
trial
protocol
approv
institut
review
board
center
patient
present
studi
provid
written
inform
consent
enrol
patient
complet
studi
week
fig
main
reason
dropout
outbreak
middl
east
respiratori
syndrom
mer
occur
korea
time
clinic
trial
sinc
dropout
particip
fear
visit
hospit
fail
conform
studi
schedul
analysi
baselin
characterist
show
particip
mean
age
year
bodi
mass
index
bmi
mm
tabl
averag
level
homair
ast
alt
iul
iul
iul
iul
respect
mean
cap
valu
dbm
mean
lsm
valu
kpa
baselin
visit
patient
prescrib
reportedli
take
metformin
week
treatment
lobeglitazon
mean
cap
valu
significantli
decreas
dbm
dbm
p
mean
valu
reduc
mm
mm
p
fig
among
particip
show
signific
decreas
cap
valu
lobeglitazon
treatment
compar
cap
valu
baselin
therefor
select
defin
lobeglitazon
respond
assess
whether
improv
hepat
steatosi
associ
better
glycem
control
examin
chang
cap
valu
patient
accord
lobeglitazon
respons
fig
treatment
mean
cap
valu
lobeglitazonerespond
group
decreas
dbm
dbm
wherea
mean
cap
valu
lobeglitazonenonrespond
group
increas
dbm
dbm
regard
glycem
control
reduct
level
significantli
differ
respond
mm
mm
nonrespond
mm
mm
p
data
indic
improv
hepat
steatosi
lobeglitazon
independ
glucoselow
effect
among
secondari
endpoint
treatment
lobeglitazon
significantli
improv
glycem
paramet
ga
fast
level
glucos
insulin
p
tabl
insulin
resist
assess
homair
amelior
lobeglitazon
treatment
among
lipid
profil
compon
lobeglitazon
treatment
significantli
increas
hdlc
p
decreas
tg
level
p
howev
tc
ldlc
level
chang
compon
hepat
profil
includ
ast
alt
show
significantli
decreas
level
week
treatment
p
addit
lsm
hscrp
valu
margin
decreas
wherea
averag
bodi
weight
increas
kg
lobeglitazon
treatment
time
point
drug
complianc
investig
whether
clinic
biochem
paramet
associ
lobeglitazon
respons
baselin
characterist
studi
popul
stratifi
respons
tabl
follow
twostep
correl
linear
regress
analys
three
statist
model
independ
variabl
tabl
analys
show
baselin
cap
valu
higher
patient
respond
lobeglitazon
dbm
fail
respond
dbm
p
paramet
show
associ
lobeglitazon
respons
firststep
correl
analys
chang
cap
valu
variou
baselin
paramet
also
demonstr
patient
higher
cap
valu
tend
larger
cap
decrement
lobeglitazon
treatment
r
p
moreov
uric
acid
level
posit
correl
chang
cap
valu
r
p
secondstep
correl
analys
show
chang
bodi
weight
well
ast
alt
level
significantli
correl
chang
cap
valu
p
correl
indic
peopl
less
increas
bodi
weight
ast
alt
level
week
also
like
show
improv
hepat
steatosi
lobeglitazon
treatment
multivari
linear
regress
analys
chang
cap
valu
follow
lobeglitazon
treatment
use
depend
factor
baselin
variabl
adjust
model
chang
cap
valu
independ
associ
baselin
cap
lsm
valu
white
blood
cell
wbc
count
alt
level
use
metformin
use
analys
would
expect
cap
decrement
lobeglitazon
treatment
subject
higher
baselin
level
cap
wbc
alt
well
metformin
user
hand
would
expect
nonrespons
lobeglitazon
higher
baselin
lsm
valu
level
model
includ
chang
clinicolaboratori
paramet
show
cap
valu
chang
independ
associ
alter
alt
level
week
treatment
std
p
combin
model
reveal
cap
valu
baselin
std
use
metformin
std
alter
alt
level
std
lsm
valu
std
signific
determin
chang
cap
valu
p
accumul
evid
regard
seriou
complic
mortal
nafld
larg
burden
public
healthcar
system
howev
optim
strategi
prevent
treatment
nafld
particularli
context
glucos
metabol
yet
fulli
investig
guidelin
put
forth
aga
aasld
recommend
tzd
pioglitazon
use
treat
patient
biopsyproven
nonalcohol
steatohepat
nash
therefor
hypothes
lobeglitazon
novel
tzd
could
allevi
hepat
steatosi
improv
hepat
function
patient
capproven
nafld
multicent
prospect
exploratori
trial
transient
liver
elastographi
assess
treatment
lobeglitazon
significantli
amelior
hepat
steatosi
patient
nafld
independ
glycem
control
lobeglitazon
treatment
also
result
improv
glycem
profil
reduc
homair
valu
lipid
profil
increas
hdlc
decreas
tg
level
liver
profil
decreas
ast
alt
level
multipl
linear
regress
analys
demonstr
hepat
fat
reduct
lobeglitazon
independ
associ
baselin
cap
valu
metformin
use
chang
lsm
alt
level
sever
clinic
studi
investig
effect
antidiabet
tzd
nafld
ratziu
et
al
report
rosiglitazon
amelior
hepat
steatosi
aminotransferas
necroinflamm
fibrosi
random
clinic
trial
rct
conduct
nash
patient
impair
glucos
toler
show
pioglitazon
treatment
improv
liver
enzym
profil
nash
histolog
fibrosi
moreov
trial
also
found
pioglitazonetr
compar
placebotr
nash
patient
show
improv
anoth
rct
conduct
nondiabet
nash
patient
show
treatment
pioglitazon
improv
steatosi
amelior
hepatocellular
injuri
fibrosi
compar
placebo
treatment
nash
patient
howev
pioglitazon
versu
vitamin
e
versu
placebo
treatment
nondiabet
patient
nonalcohol
steatohepat
piven
trial
multicent
rct
nondiabet
patient
nash
show
pioglitazonetr
patient
compar
placebotr
patient
achiev
improv
hepatosteatosi
assess
histolog
p
studi
show
nafld
patient
respond
lobeglitazon
treatment
compar
improv
steatosi
pioglitazon
treatment
observ
piven
trial
interestingli
recent
rct
metaanalysi
show
tzd
improv
hepat
steatosi
inflamm
fibrosi
similarli
studi
demonstr
lobeglitazon
treatment
nafld
patient
improv
hepat
steatosi
assess
cap
liver
enzym
profil
assess
aminotransferas
level
liver
fibrosi
base
measur
liver
stiff
liverbiopsi
proven
studi
could
assess
alter
hepat
inflamm
hepatocellular
balloon
follow
treatment
regard
cap
previou
studi
analyz
associ
cap
valu
liver
histolog
particularli
nafld
patient
highgrad
steatosi
elev
bmi
verifi
util
cap
noninvas
tool
diagnos
monitor
nafld
patient
howev
despit
rel
high
accuraci
detect
hepat
steatosi
agreement
histolog
analysi
cap
hepat
fat
quantif
vari
among
individu
mild
steatosi
thu
studi
recruit
subject
nafld
use
higher
cutoff
cap
valu
dbm
previou
studi
suggest
better
glycem
control
affect
improv
fatti
liver
patient
respons
drug
treatment
thu
could
argu
improv
glycem
control
alon
might
respons
reduc
hepat
steatosi
address
concern
current
studi
classifi
patient
two
group
accord
lobeglitazon
respons
trial
two
subject
one
respond
group
nonrespond
group
receiv
mg
glimepirid
rescu
therapi
except
two
subject
particip
show
improv
glycem
control
assess
ga
level
interestingli
although
cap
valu
significantli
reduc
respond
group
valu
significantli
reduc
respond
nonrespond
group
data
suggest
reduct
hepatosteatosi
independ
degre
glycem
control
studi
investig
pharmacolog
mechan
tzd
alter
fat
content
adipocyt
mechan
thought
posit
affect
distribut
fat
mass
prolifer
adipocyt
result
weight
gain
nevertheless
tzd
also
shown
reduc
liver
fat
content
enhanc
peripher
tissu
glucos
uptak
regard
neg
side
effect
tzd
weight
gain
view
balanc
manner
previou
studi
shown
pioglitazon
treatment
increas
bodi
weight
kg
depend
studi
studi
lobeglitazon
treatment
show
lower
increas
averag
bodi
weight
kg
kg
kg
p
similar
weight
gain
rang
kg
observ
clinic
trial
use
mgday
lobeglitazon
studi
identifi
predict
factor
associ
lobeglitazon
respons
found
individu
higher
valu
cap
wbc
alt
lower
valu
lsm
baselin
show
greater
reduct
hepat
fat
follow
lobeglitazon
treatment
although
previou
trial
tzd
analyz
predictor
respons
trial
rosiglitazon
show
respond
lower
baselin
level
higher
baselin
amount
steatosi
nonrespond
consist
find
similar
previou
studi
also
observ
greater
reduct
alt
level
respond
compar
observ
nonrespond
follow
treatment
previou
studi
also
shown
respond
show
greater
increment
serum
adiponectin
level
tzd
treatment
nonrespond
furthermor
ratziu
et
al
report
greater
reduct
insulin
level
respond
rosiglitazon
nonrespond
observ
trial
differ
like
due
fact
patient
studi
diabet
wherea
patient
ratziu
et
al
studi
diabet
moreov
multipl
regress
analysi
demonstr
patient
treat
metformin
lobeglitazon
show
greater
reduct
hepat
steatosi
patient
treat
lobeglitazon
alon
previou
rct
shown
inconsist
effect
use
metformin
alon
treat
nafld
thu
combin
metformin
lobeglitazon
may
synergist
act
reduc
hepat
fat
one
plausibl
explan
could
act
togeth
pathogen
heterogen
nafld
exampl
lobeglitazon
may
play
role
decreas
avail
plasma
fatti
acid
aris
adipos
tissu
abat
lipolysi
posit
distribut
fat
mass
hand
metformin
may
activ
either
fatti
acid
oxid
lipophagi
well
mitophagi
via
upregul
adenosin
monophosph
kinas
andor
sirtuin
pathway
addit
metformin
may
amelior
advers
effect
weight
gain
caus
tzd
treatment
present
studi
limit
address
futur
studi
lobeglitazon
novel
tzd
thu
longterm
safeti
treat
patient
nafld
establish
moreov
find
current
studi
taken
caution
clinic
trial
includ
rel
small
number
particip
without
qualiti
control
cap
measur
conduct
five
center
addit
perform
liver
biopsi
gold
standard
method
evalu
statu
nafld
highli
invas
costli
procedur
furthermor
studi
clearli
show
lobeglitazon
work
nafld
final
perform
singlearm
trial
without
placebo
activ
arm
howev
even
limit
current
studi
sever
strength
first
conduct
studi
novel
drug
lobeglitazon
assess
addit
benefit
nafld
patient
second
best
knowledg
first
trial
demonstr
cap
use
simpl
noninvas
tool
quantifi
monitor
chang
liver
fat
content
intervent
final
identifi
sever
paramet
may
use
predict
nafldpati
respons
lobeglitazon
treatment
conclus
investig
effect
antidiabet
drug
lobeglitazon
patient
nafld
use
transient
liver
elastographi
cap
glucometabol
profil
analysi
found
method
effect
lower
glucos
level
also
reduc
intrahepat
fat
content
furthermor
increas
steatosi
grade
metformin
use
patient
baselin
well
decreas
alt
lsm
level
treatment
reliabl
factor
predict
respons
lobeglitazon
togeth
data
indic
lobeglitazon
valid
novel
therapeut
use
treat
nafld
patient
